First Benelux Joint Pricing and Reimbursement Pilot Fails Over Vertex’ Orkambi
The first pilot for the Benelux joint pricing and reimbursement process has failed. Negotiations between Vertex and the ministries of health in Belgium and the Netherlands have ended with no agreement on price for cystic fibrosis drug Orkambi.
You may also be interested in...
Compulsory licensing, new R&D models, and pharmaceutical compounding are among measures that could help secure lower drugs prices, according to a report from the Dutch Council for Public Health and Society.
The BeNeLuxA collaboration for sustainable access to medicines may soon expand further. Future partners could include France and non-EU markets.
Two new BeNeLuxA pilots are underway and a website detailing information about the wider initiative is likely to go live soon.